中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 4
Apr.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(4): 706-711

Protective effect of Genistein against nonalcoholic fatty liver disease in ovariectomized mice and its mechanism

DOI: 10.12449/JCH240411
  • 1.

    Department of Pharmacy，Suzhou Ninth Hospital Affiliated to Suzhou University，Suzhou，Jiangsu 215200，China

  • 2.

    School of Pharmacy，Anhui Medical University，Hefei 230032，China

Research funding:

Suzhou Science and Technology Development Plan (SKJYD2021153)

More Information
  • Corresponding author: JIN Yong， jinyong@ahmu.edu.cn （ORCID： 0000-0003-3133-7952）
  • Received Date: 2023-07-07
  • Accepted Date: 2023-09-12
  • Published Date: 2024-04-25
    Abstract
  •   Objective  To investigate the protective effect of Genistein against nonalcoholic fatty liver disease （NAFLD） in ovariectomized （OVX） mice and its mechanism.  Methods  A total of 40 female C57BL/6 mice， aged 6 weeks， were used to establish an OVX mouse model， and then they were randomly divided into blank group， 4-week model group， 6-week model group， 8-week model group， and 10-week model group， with 8 mice in each group. Under the same environmental conditions， the mice were given high-fat diet for modeling， and pathological examination showed that NAFLD was successfully induced by 10-week high-fat diet. Another 40 female C57BL/6 mice， aged 6 weeks， were randomly divided into blank group， sham operation group （Sham group）， OVX group， OVX+L-Genistein （4 mg/kg body weight） group， and OVX+H-Genistein （8 mg/kg body weight） group. The mice in the Sham group were given the same procedure of OVX， without the ligation of the ovarian artery and the resection of the ovary. The mice in the blank group were given normal diet， and those in the other groups were given high-fat diet. Genistein was dissolved in DMSO， and the mice in the Sham group and the OVX group were treated with solvent solution alone by gavage， once a day for 10 consecutive weeks. Body weight and visceral index were recorded， and the mice were sacrificed to collect serum and liver tissue. Kits were used to measure the activity of alanine aminotransferase （ALT） and aspartate aminotransferase （AST） and the serum levels of triglyceride （TG） and total cholesterol （TC）， and HE staining and oil red O staining were used to observe liver histopathology； Western blot was used to measure the protein expression levels of sterol regulatory element-binding protein 1c （SREBP-1c） and peroxisome proliferator-activated receptor alpha （PPARα） associated with lipid metabolism in liver tissue. A one-way analysis of variance was used for comparison of continuous data between multiple groups， and the Dunnett-t test was used for further comparison between two groups.  Results  After 10 weeks of high-fat diet， the OVX+L-Genistein group and the OVX+H-Genistein group had significantly lower body weight， liver index， and liver tissue weight （all P<0.05）. In addition， Genistein significantly downregulated the serum levels of TC and TG （P<0.05） and reduced the activities of serum AST and ALT （P<0.05）. HE and oil red O staining showed that compared with the OVX group， the OVX+L-Genistein group and the OVX+H-Genistein group had a significant reduction in the accumulation of lipid droplets. Western blot showed that after Genistein intervention， there was a significant reduction in the protein expression level of SREBP-1c and a significant increase in the protein expression level of PPARα （P<0.05）.  Conclusion  Genistein exerts a protective effect against NAFLD in OVX mice possibly by regulating the expression of SREBP-1c and PPARα， thereby promoting fatty acid oxidation and inhibiting liver lipid synthesis.

     

    • FullText(HTML)
  • loading
    • References(17)
  • [1]
    PAFILI K, RODEN M. Nonalcoholic fatty liver disease(NAFLD) from pathogenesis to treatment concepts in humans[J]. Mol Metab, 2021, 50: 101122. DOI: 10.1016/j.molmet.2020.101122.
    [2]
    YU Y, CAI JJ, SHE ZG, et al. Insights into the epidemiology, pathogenesis, and therapeutics of nonalcoholic fatty liver diseases[J]. Adv Sci(Weinh), 2018, 6( 4): 1801585. DOI: 10.1002/advs.201801585.
    [3]
    MANNE V, HANDA P, KOWDLEY KV. Current treatment of non-alcoholic fatty liver disease[J]. Clin Liver Dis, 2018, 22( 1): 23- 37. DOI: 10.1016/j.cld.2017.08.007.
    [4]
    CHOUDHURI G, SHAH S, KULKARNI A, et al. Non-alcoholic steatohepatitis in asians: Current perspectives and future directions[J]. Cureus, 2023, 15( 8): e42852. DOI: 10.7759/cureus.42852.
    [5]
    PAWLOWSKI JW, MARTIN BR, MCCABE GP, et al. Impact of equol-producing capacity and soy-isoflavone profiles of supplements on bone calcium retention in postmenopausal women: A randomized crossover trial[J]. Am J Clin Nutr, 2015, 102( 3): 695- 703. DOI: 10.3945/ajcn.114.093906.
    [6]
    ZHAO L, WANG Y, LIU J, et al. Protective effects of genistein and puerarin against chronic alcohol-induced liver injury in mice via antioxidant, anti-inflammatory, and anti-apoptotic mechanisms[J]. J Agric Food Chem, 2016, 64( 38): 7291- 7297. DOI: 10.1021/acs.jafc.6b02907.
    [7]
    AMANAT S, EFTEKHARI MH, FARAROUEI M, et al. Genistein supplementation improves insulin resistance and inflammatory state in non-alcoholic fatty liver patients: A randomized, controlled trial[J]. Clin Nutr, 2018, 37( 4): 1210- 1215. DOI: 10.1016/j.clnu.2017.05.028.
    [8]
    XIA HG, ZHU XY, ZHANG XY, et al. Alpha-naphthoflavone attenuates non-alcoholic fatty liver disease in oleic acid-treated HepG2 hepatocytes and in high fat diet-fed mice[J]. Biomed Pharmacother, 2019, 118: 109287. DOI: 10.1016/j.biopha.2019.109287.
    [9]
    MOLINA-MOLINA E, FURTADO GE, JONES JG, et al. The advantages of physical exercise as a preventive strategy against NAFLD in postmenopausal women[J]. Eur J Clin Invest, 2022, 52( 3): e13731. DOI: 10.1111/eci.13731.
    [10]
    ZHU XY, XIA HG, WANG ZH, et al. Invitro and invivo approaches for identifying the role of aryl hydrocarbon receptor in the development of nonalcoholic fatty liver disease[J]. Toxicol Lett, 2020, 319: 85- 94. DOI: 10.1016/j.toxlet.2019.10.010.
    [11]
    CALIGIONI CS. Assessing reproductive status/stages in mice[J]. Curr Protoc Neurosci, 2009, Appendix 4: Appendix 4 I. DOI: 10.1002/0471142301.nsa04is48.
    [12]
    DEMIR M, BORNSTEIN SR, MANTZOROS CS, et al. Liver fat as risk factor of hepatic and cardiometabolic diseases[J]. Obes Rev, 2023, 24( 10): e13612. DOI: 10.1111/obr.13612.
    [13]
    POWELL EE, WONG VWS, RINELLA M. Non-alcoholic fatty liver disease[J]. Lancet, 2021, 397( 10290): 2212- 2224. DOI: 10.1016/S0140-6736(20)32511-3.
    [14]
    WANG CE, XU WT, GONG J, et al. Research progress in the treatment of non-alcoholic fatty liver disease[J]. Clin J Med Offic, 2022, 50( 9): 897- 899, 903. DOI: 10.16680/j.1671-3826.2022.09.06.

    王彩娥, 许文涛, 宫建, 等. 非酒精性脂肪性肝病治疗研究进展[J]. 临床军医杂志, 2022, 50( 9): 897- 899, 903. DOI: 10.16680/j.1671-3826.2022.09.06.
    [15]
    FRIEDMAN SL, NEUSCHWANDER-TETRI BA, RINELLA M, et al. Mechanisms of NAFLD development and therapeutic strategies[J]. Nat Med, 2018, 24( 7): 908- 922. DOI: 10.1038/s41591-018-0104-9.
    [16]
    ALEXANDER KS, ZAKAI NA, LIDOFSKY SD, et al. Non-alcoholic fatty liver disease, liver biomarkers and stroke risk: The reasons for geographic and racial differences in stroke cohort[J]. PLoS One, 2018, 13( 3): e0194153. DOI: 10.1371/journal.pone.0194153.
    [17]
    KAWAMURA S, MATSUSHITA Y, KUROSAKI S, et al. Inhibiting SCAP/SREBP exacerbates liver injury and carcinogenesis in murine nonalcoholic steatohepatitis[J]. J Clin Invest, 2022, 132( 11): e151895. DOI: 10.1172/JCI151895.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(5)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (337) PDF downloads(40) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return